Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Humacyte, Inc. (HUMA)

Humacyte Q3 Symvess sales rise to $1.0 million; net loss narrows to $15.5 million

Positive Impact 3 of 5 earnings

Humacyte reported third-quarter 2026 results with Symvess sales of $1.0 million, up from $0.4 million in the second quarter and $0.7 million a year earlier. The quarterly net loss narrowed to $15.5 million, or $0.06 per share, from $17.5 million, or $0.11 per share, a year earlier, but the nine-month net loss widened to $70.0 million, mainly due to a non-cash remeasurement of the contingent earnout liability.

Key points

  • Q3 2026 Symvess sales were $1.0 million, versus $0.4 million in Q2 2026 and $0.7 million in Q3 2025.
  • Q3 2026 net loss was $15.5 million ($0.06 per share), compared with $17.5 million ($0.11 per share) in Q3 2025.
  • Nine-month 2026 net loss was $70.0 million, versus $16.0 million in the prior-year period, driven by a non-cash earnout remeasurement.
  • October 2026 Symvess sales were $0.8 million; cash and equivalents were $64.9 million as of September 30, 2026.

The filing

CompanyHumacyte, Inc. (HUMA)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:05 AM ET
Accession number0001193125-26-454402

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:11 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.